Company Profile
Updated: 13-NOV-09AstraZeneca S.A.
International subsidiary
Edificio Torre de los Profesionales, Yaguaron 1407, Montevideo, 11000, Uruguay
()598 02 901 8900, 598 02 902 3689 fax, http://www.astrazeneca.com.uy
Primary SIC: Pharmaceutical Preparations, Primary NAICS: Pharmaceutical Preparation Manufacturing
Description: Manufacturing: Manufacture and sale of pharmaceutical products, clinical research
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
!Vive Tu Vida! Get Up! Get Moving! Third Annual Houston Family Fitness Celebration Announced.
Obesity, Fitness & Wellness Week; 11/21/2009; 635 words; ...at the Mason Park in Houston's East End located at 541 South...take for you and your family's health," said Dr. Jane L...family health events. We thank AstraZeneca for helping us make heart health...about the events, and the U.S. Soccer Foundation and the U...
MAP Pharmaceuticals Reports Third Quarter of 2009 Financial Results.(Financial report)
Pediatrics Week; 11/21/2009; 1478 words; ...the termination of the AstraZeneca AB license agreement in...therapy," said Timothy S. Nelson, President and...migraine sufferers in the U.S., including many who...UDB), the company's nebulized pediatric asthma...license agreement with AstraZeneca. On July 8, 2009, the...
New cancer study results from National Cancer Institute described.
Blood Weekly; 11/19/2009; 824 words; ...features required for tumorigenesis. Small molecule inhibitors, such as Cephalon's CEP-701, are in phase 1 and 2 clinical trials, and a series of AstraZeneca Trk inhibitors are poised to enter the clinic. As monotherapy, inhibitors may be...
Zyngenia, Inc. Raises $10 Million in Series a Funding.
Gene Therapy Weekly; 11/19/2009; 1330 words; ...III, Ph.D., Zyngenia's Chief Scientific Officer, is...acquired by Alexion). Zyngenia's founding management team also...will also join the company's board of directors. Mr. Mott...MedImmune, which was acquired by AstraZeneca for $15.6 billion in 2007...
Piedmont Triad, N.C., biotech news/Targacept Awarded Grant from Michael J. Fox Foundation to Conduct Research in the Treatment of Side Effects of Parkinsons Disease Therapy.
Biotech Week; 11/18/2009; 1457 words; ...diseases and disorders. Targacept's product candidates selectively...hyperactivity disorder, Alzheimer's disease and cognitive dysfunction...focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept's news releases are available on...
Recent News Articles
- AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent.
PR Newswire - November 19, 2009 - AstraZeneca applies for US marketing approval of Brilinta.
Nordic Business Report - November 19, 2009 - Studies from AstraZeneca have provided new information about pharmacokinetics.
Biotech Week - November 18, 2009 - Quintiles Announces Clinical Pharmacology Alliance with AstraZeneca.(Clinical report)
Biotech Week - November 18, 2009
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning